Literature DB >> 23511752

C3 glomerulopathies. A new perspective on glomerular diseases.

Cristina Rabasco-Ruiz1, Ana Huerta-Arroyo, Jara Caro-Espada, Eduardo Gutiérrez-Martínez, Manuel Praga-Terente.   

Abstract

Membranoproliferative glomerulonephritis denotes a general pattern of glomerular injury that is easily recognised by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition location, while immunofluorescence typically detects the composition of electron-dense deposits. A C3 glomerulopathy (C3G) is a recently described entity, a proliferative glomerulonephritis (usually but not always), with a MPGN pattern on light microscopy, with C3 staining alone on immunofluorescence, implicating hyperactivity of the alternative complement pathway. The evaluation of C3G in a patient should focus on the complement cascade, as deregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs, as eculizumab. In this review, we summarise the pathogenesis of the C3 glomerulopathies, focusing on the role of complement, the patient cohorts recently reported and options of treatment up to the current moment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23511752     DOI: 10.3265/Nefrologia.pre2012.Nov.11802

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  8 in total

1.  A case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection.

Authors:  Marina Asano; Takashi Oda; Masashi Mizuno
Journal:  CEN Case Rep       Date:  2021-11-19

2.  Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Authors:  Ozan Ozkaya; Hulya Nalcacioglu; Demet Tekcan; Gurkan Genc; Bilge Can Meydan; B Handan Ozdemir; M Kemal Baysal; Hasan Tahsin Keceligil
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714

3.  The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience.

Authors:  J Pavinic; M Miglinas
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

4.  Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.

Authors:  Yukihiko Kawasaki; Syuto Kanno; Atsushi Ono; Yuichi Suzuki; Shinichiro Ohara; Masatoki Sato; Kazuhide Suyama; Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Pediatr Nephrol       Date:  2016-02-04       Impact factor: 3.714

5.  Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy.

Authors:  Jose Luis Espinosa-Figueroa; Marta Cano-Megías; Patricia Martínez-Miguel; Mercedes Velo-Plaza
Journal:  BMJ Case Rep       Date:  2018-02-23

6.  Predictive factors for poor outcome in pediatric C3 glomerulonephritis.

Authors:  Mamiko Hosoya; Yukihiko Kawasaki; Ryo Maeda; Masatoki Sato; Kazuhide Suyama; Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2018-10-27

7.  Successful treatment of infectious endocarditis associated glomerulonephritis mimicking c3 glomerulonephritis in a case with no previous cardiac disease.

Authors:  Yosuke Kawamorita; Yoshihide Fujigaki; Atsuko Imase; Shigeyuki Arai; Yoshifuru Tamura; Masayuki Tanemoto; Hiroshi Uozaki; Yutaka Yamaguchi; Shunya Uchida
Journal:  Case Rep Nephrol       Date:  2014-11-23

8.  Timing of eculizumab therapy for C3 glomerulonephritis.

Authors:  Laura Rodriguez-Osorio; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2015-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.